6 0 1 0 1 O
weeks 2 7 2 7 O
for 8 11 8 11 O
mitomycin 12 21 12 21 B-treatment
- 21 22 21 22 I-treatment
C 22 23 22 23 I-treatment
and 24 27 24 27 O
nitrosoureas 28 40 28 40 B-treatment
) 40 41 40 41 O
, 41 42 41 42 O
and 43 46 43 46 O
adequately 47 57 47 57 O
recovered 58 67 58 67 O
from 68 72 68 72 O
adverse 73 80 73 80 O
effects 81 88 81 88 O
from 89 93 89 93 O
prior 94 99 94 99 B-treatment
therapy 100 107 100 107 I-treatment
to 108 110 108 110 O
meet 111 115 111 115 O
all 116 119 116 119 O
other 120 125 120 125 O
eligibility 126 137 126 137 O
criteria 138 146 138 146 O

Absolute 0 8 147 155 B-clinical_variable
neutrophil 9 19 156 166 I-clinical_variable
count 20 25 167 172 I-clinical_variable
= 26 27 173 174 O
< 27 28 174 175 O
1,500 29 34 176 181 B-upper_bound
/ 34 35 181 182 I-upper_bound
uL 35 37 182 184 I-upper_bound

Aspartate 0 9 185 194 B-clinical_variable
aminotransferase 10 26 195 211 I-clinical_variable
( 27 28 212 213 I-clinical_variable
AST)/alanine 28 40 213 225 I-clinical_variable
aminotransferase 41 57 226 242 I-clinical_variable
( 58 59 243 244 I-clinical_variable
ALT 59 62 244 247 I-clinical_variable
) 62 63 247 248 I-clinical_variable
= 64 65 249 250 O
< 65 66 250 251 O
2.5 67 70 252 255 B-upper_bound
x 71 72 256 257 I-upper_bound
institutional 73 86 258 271 I-upper_bound
upper 87 92 272 277 I-upper_bound
limit 93 98 278 283 I-upper_bound
of 99 101 284 286 I-upper_bound
normal 102 108 287 293 I-upper_bound

Creatinine 0 10 294 304 B-clinical_variable
within 11 17 305 311 O
normal 18 24 312 318 O
institutional 25 38 319 332 O
limits 39 45 333 339 O

Eastern 0 7 340 347 B-clinical_variable
Cooperative 8 19 348 359 I-clinical_variable
Oncology 20 28 360 368 I-clinical_variable
Group 29 34 369 374 I-clinical_variable
( 35 36 375 376 I-clinical_variable
ECOG 36 40 376 380 I-clinical_variable
) 40 41 380 381 I-clinical_variable
performance 42 53 382 393 I-clinical_variable
status 54 60 394 400 I-clinical_variable
0 61 62 401 402 B-lower_bound
or 63 65 403 405 O
1 66 67 406 407 B-upper_bound

Electrocardiogram 0 17 408 425 B-treatment
( 18 19 426 427 I-treatment
ECG 19 22 427 430 I-treatment
) 22 23 430 431 I-treatment
corrected 24 33 432 441 O
QT 34 36 442 444 B-clinical_variable
( 37 38 445 446 I-clinical_variable
QTC 38 41 446 449 I-clinical_variable
) 41 42 449 450 I-clinical_variable
< 43 44 451 452 O
450 45 48 453 456 B-upper_bound
msec 49 53 457 461 I-upper_bound

Fasting 0 7 462 469 B-clinical_variable
glucose 8 15 470 477 I-clinical_variable
within 16 22 478 484 O
normal 23 29 485 491 O
limits 30 36 492 498 O

History 0 7 499 506 O
of 8 10 507 509 O
allergic 11 19 510 518 O
reactions 20 29 519 528 O
attributed 30 40 529 539 O
to 41 43 540 542 O
compounds 44 53 543 552 O
of 54 56 553 555 O
similar 57 64 556 563 O
chemical 65 73 564 572 O
or 74 76 573 575 O
biologic 77 85 576 584 O
composition 86 97 585 596 O
to 98 100 597 599 O
PTX-200 101 108 600 607 B-allergy_name
or 109 111 608 610 O
other 112 117 611 616 O
agents 118 124 617 623 O
used 125 129 624 628 O
in 130 132 629 631 O
the 133 136 632 635 O
study 137 142 636 641 O
( 143 144 642 643 O
e.g. 144 148 643 647 O
, 148 149 647 648 O
imidazoles 150 160 649 659 B-allergy_name
, 160 161 659 660 O
quinolones 162 172 661 671 B-allergy_name
) 172 173 671 672 O

Human 0 5 673 678 B-chronic_disease
immunodeficiency 6 22 679 695 I-chronic_disease
virus 23 28 696 701 I-chronic_disease
( 29 30 702 703 I-chronic_disease
HIV)-positive 30 43 703 716 I-chronic_disease
patients 44 52 717 725 O
receiving 53 62 726 735 O
combination 63 74 736 747 O
antiretroviral 75 89 748 762 B-treatment
therapy 90 97 763 770 I-treatment
are 98 101 771 774 O
excluded 102 110 775 783 O
from 111 115 784 788 O
the 116 119 789 792 O
study 120 125 793 798 O

LVEF 0 4 799 803 B-clinical_variable
at 5 7 804 806 O
or 8 10 807 809 O
above 11 16 810 815 O
institutional 17 30 816 829 B-clinical_variable
lower 31 36 830 835 I-clinical_variable
limits 37 43 836 842 I-clinical_variable
of 44 46 843 845 I-clinical_variable
normal 47 53 846 852 I-clinical_variable
( 54 55 853 854 O
> 55 56 854 855 O
= 56 57 855 856 O
50 58 60 857 859 B-lower_bound
% 60 61 859 860 I-lower_bound
) 61 62 860 861 O

Left 0 4 862 866 B-clinical_variable
ventricular 5 16 867 878 I-clinical_variable
ejection 17 25 879 887 I-clinical_variable
fraction 26 34 888 896 I-clinical_variable
( 35 36 897 898 I-clinical_variable
LVEF 36 40 898 902 I-clinical_variable
) 40 41 902 903 I-clinical_variable
within 42 48 904 910 O
normal 49 55 911 917 O
institutional 56 69 918 931 O
limits 70 76 932 938 O

Leukocytes 0 10 939 949 B-clinical_variable
> 11 12 950 951 O
= 12 13 951 952 O
3,000 14 19 953 958 B-lower_bound
/ 19 20 958 959 I-lower_bound
uL 20 22 959 961 I-lower_bound

No 0 2 962 964 O
prior 3 8 965 970 O
chemotherapy 9 21 971 983 B-treatment
, 21 22 983 984 O
irradiation 23 34 985 996 B-treatment
, 34 35 996 997 O
or 36 38 998 1000 O
definitive 39 49 1001 1011 O
therapeutic 50 61 1012 1023 B-treatment
surgery 62 69 1024 1031 I-treatment
( 70 71 1032 1033 O
e.g. 71 75 1033 1037 O
, 75 76 1037 1038 O
mastectomy 77 87 1039 1049 B-treatment
or 88 90 1050 1052 O
lumpectomy 91 101 1053 1063 B-treatment
or 102 104 1064 1066 O
axillary 105 113 1067 1075 B-treatment
dissection 114 124 1076 1086 I-treatment
) 124 125 1086 1087 O
for 126 129 1088 1091 O
this 130 134 1092 1096 O
malignancy 135 145 1097 1107 B-cancer

Patients 0 8 1108 1116 O
may 9 12 1117 1120 O
not 13 16 1121 1124 O
be 17 19 1125 1127 O
receiving 20 29 1128 1137 O
any 30 33 1138 1141 O
other 34 39 1142 1147 O
investigational 40 55 1148 1163 B-treatment
agents 56 62 1164 1170 I-treatment
during 63 69 1171 1177 I-treatment
protocol 70 78 1178 1186 I-treatment
therapy 79 86 1187 1194 I-treatment

Patients 0 8 1195 1203 O
must 9 13 1204 1208 O
be 14 16 1209 1211 O
disease 17 24 1212 1219 O
- 24 25 1219 1220 O
free 25 29 1220 1224 O
of 30 32 1225 1227 O
prior 33 38 1228 1233 O
invasive 39 47 1234 1242 O
malignancies 48 60 1243 1255 B-cancer
for 61 64 1256 1259 O
> 65 66 1260 1261 O
= 66 67 1261 1262 O
2 68 69 1263 1264 B-lower_bound
years 70 75 1265 1270 I-lower_bound
with 76 80 1271 1275 O
the 81 84 1276 1279 O
exception 85 94 1280 1289 O
of 95 97 1290 1292 O
curatively 98 108 1293 1303 O
- 108 109 1303 1304 O
treated 109 116 1304 1311 O
basal 117 122 1312 1317 B-cancer
cell 123 127 1318 1322 I-cancer

Patients 0 8 1323 1331 O
must 9 13 1332 1336 O
have 14 18 1337 1341 O
histologically 19 33 1342 1356 O
or 34 36 1357 1359 O
cytologically 37 50 1360 1373 O
confirmed 51 60 1374 1383 O
adenocarcinoma 61 75 1384 1398 B-cancer
of 76 78 1399 1401 I-cancer
the 79 82 1402 1405 I-cancer
breast 83 89 1406 1412 I-cancer
associated 90 100 1413 1423 O
with 101 105 1424 1428 O
clinical 106 114 1429 1437 O
stage 115 120 1438 1443 O
: 120 121 1443 1444 O
IV 122 124 1445 1447 O
( 125 126 1448 1449 O
see 126 129 1449 1452 O
American 130 138 1453 1461 O
Joint 139 144 1462 1467 O
Committee 145 154 1468 1477 O
on 155 157 1478 1480 O
Cancer 158 164 1481 1487 O
[ 165 166 1488 1489 O
AJCC 166 170 1489 1493 O
] 170 171 1493 1494 O
staging 172 179 1495 1502 O
criteria 180 188 1503 1511 O
, 188 189 1511 1512 O
7th 190 193 1513 1516 O
edition 194 201 1517 1524 O
) 201 202 1524 1525 O
or 203 205 1526 1528 O
stage 206 211 1529 1534 B-lower_bound
IIB 212 215 1535 1538 I-lower_bound
- 215 216 1538 1539 O
IIIC 216 220 1539 1543 B-upper_bound
( 221 222 1544 1545 O
expansion 222 231 1545 1554 O
cohort 232 238 1555 1561 O
only 239 243 1562 1566 O
) 243 244 1566 1567 O

Patients 0 8 1568 1576 O
must 9 13 1577 1581 O
have 14 18 1582 1586 O
histologically 19 33 1587 1601 O
or 34 36 1602 1604 O
cytologically 37 50 1605 1618 O
confirmed 51 60 1619 1628 O
adenocarcinoma 61 75 1629 1643 B-cancer
of 76 78 1644 1646 I-cancer
the 79 82 1647 1650 I-cancer
breast 83 89 1651 1657 I-cancer
associated 90 100 1658 1668 O
with 101 105 1669 1673 O
the 106 109 1674 1677 O
following 110 119 1678 1687 O
clinical 120 128 1688 1696 B-cancer
stage 129 134 1697 1702 I-cancer
: 134 135 1702 1703 I-cancer
IIB 136 139 1704 1707 I-cancer
, 139 140 1707 1708 I-cancer
IIIA 141 145 1709 1713 I-cancer
, 145 146 1713 1714 I-cancer
IIIB 147 151 1715 1719 I-cancer
, 151 152 1719 1720 I-cancer
or 153 155 1721 1723 I-cancer
IIIC 156 160 1724 1728 I-cancer
( 161 162 1729 1730 O
see 162 165 1730 1733 O
AJCC 166 170 1734 1738 O
staging 171 178 1739 1746 O
criteria 179 187 1747 1755 O
, 187 188 1755 1756 O
7th 189 192 1757 1760 O
edition 193 200 1761 1768 O
) 200 201 1768 1769 O

Patients 0 8 1770 1778 O
who 9 12 1779 1782 O
received 13 21 1783 1791 O
tamoxifen 22 31 1792 1801 B-treatment
or 32 34 1802 1804 O
another 35 42 1805 1812 B-treatment
selective 43 52 1813 1822 I-treatment
estrogen 53 61 1823 1831 I-treatment
receptor 62 70 1832 1840 I-treatment
modulator 71 80 1841 1850 I-treatment
( 81 82 1851 1852 I-treatment
SERM 82 86 1852 1856 I-treatment
) 86 87 1856 1857 I-treatment
for 88 91 1858 1861 O
prevention 92 102 1862 1872 O
or 103 105 1873 1875 O
treatment 106 115 1876 1885 B-treatment
of 116 118 1886 1888 O
breast 119 125 1889 1895 B-cancer
cancer 126 132 1896 1902 I-cancer
or 133 135 1903 1905 O
for 136 139 1906 1909 O
other 140 145 1910 1915 O
indications 146 157 1916 1927 O

Platelets 0 9 1928 1937 B-clinical_variable
> 10 11 1938 1939 O
= 11 12 1939 1940 O
100,000 13 20 1941 1948 B-lower_bound
/ 20 21 1948 1949 I-lower_bound
uL 21 23 1949 1951 I-lower_bound

Pregnant 0 8 1952 1960 B-pregnancy
women 9 14 1961 1966 B-gender
are 15 18 1967 1970 O
excluded 19 27 1971 1979 O
from 28 32 1980 1984 O
this 33 37 1985 1989 O
study 38 43 1990 1995 O

Serum 0 5 1996 2001 B-clinical_variable
calcium 6 13 2002 2009 I-clinical_variable
within 14 20 2010 2016 O
normal 21 27 2017 2023 O
institutional 28 41 2024 2037 O
limits 42 48 2038 2044 O

Serum 0 5 2045 2050 B-clinical_variable
phosphorus 6 16 2051 2061 I-clinical_variable
within 17 23 2062 2068 O
normal 24 30 2069 2075 O
institutional 31 44 2076 2089 O
limits 45 51 2090 2096 O

Total 0 5 2097 2102 O
bilirubin 6 15 2103 2112 B-clinical_variable
within 16 22 2113 2119 O
normal 23 29 2120 2126 O
institutional 30 43 2127 2140 O
limits 44 50 2141 2147 O

Uncontrolled 0 12 2148 2160 O
intercurrent 13 25 2161 2173 B-chronic_disease
illness 26 33 2174 2181 I-chronic_disease
including 34 43 2182 2191 O
, 43 44 2191 2192 O
but 45 48 2193 2196 O
not 49 52 2197 2200 O
limited 53 60 2201 2208 O
to 61 63 2209 2211 O
, 63 64 2211 2212 O
ongoing 65 72 2213 2220 O
or 73 75 2221 2223 O
active 76 82 2224 2230 B-chronic_disease
infection 83 92 2231 2240 I-chronic_disease
, 92 93 2240 2241 O
diabetes 94 102 2242 2250 B-chronic_disease
mellitus 103 111 2251 2259 I-chronic_disease
requiring 112 121 2260 2269 O
therapy 122 129 2270 2277 B-treatment
( 130 131 2278 2279 O
insulin 131 138 2279 2286 B-treatment
or 139 141 2287 2289 O
oral 142 146 2290 2294 B-treatment
hypoglycemic 147 159 2295 2307 I-treatment
agents 160 166 2308 2314 I-treatment
) 166 167 2314 2315 O
, 167 168 2315 2316 O
congenital 169 179 2317 2327 B-chronic_disease
prolonged 180 189 2328 2337 I-chronic_disease
QT 190 192 2338 2340 I-chronic_disease
syndrome 193 201 2341 2349 I-chronic_disease
, 201 202 2349 2350 O
requirement 203 214 2351 2362 O
for 215 218 2363 2366 O
a 219 220 2367 2368 O
drug 221 225 2369 2373 O
known 226 231 2374 2379 O
to 232 234 2380 2382 O
prolong 235 242 2383 2390 O
the 243 246 2391 2394 O
QT 247 249 2395 2397 O
interval 250 258 2398 2406 O
, 258 259 2406 2407 O
a 260 261 2408 2409 O
history 262 269 2410 2417 O
of 270 272 2418 2420 O
QT 273 275 2421 2423 B-treatment
prolongation 276 288 2424 2436 I-treatment

Up 0 2 2437 2439 O
to 3 5 2440 2442 O
two 6 9 2443 2446 O
prior 10 15 2447 2452 B-treatment
non 16 19 2453 2456 I-treatment
- 19 20 2456 2457 I-treatment
taxane 20 26 2457 2463 I-treatment
chemotherapy 27 39 2464 2476 I-treatment
regimens 40 48 2477 2485 O
for 49 52 2486 2489 O
metastatic 53 63 2490 2500 B-cancer
disease 64 71 2501 2508 I-cancer
are 72 75 2509 2512 O
permitted 76 85 2513 2522 O
for 86 89 2523 2526 O
patients 90 98 2527 2535 O
enrolled 99 107 2536 2544 O
on 108 110 2545 2547 O
the 111 114 2548 2551 O
phase 115 120 2552 2557 O
I 121 122 2558 2559 O
portion 123 130 2560 2567 O
of 131 133 2568 2570 O
the 134 137 2571 2574 O
trial 138 143 2575 2580 O

Women 0 5 2581 2586 B-gender
of 6 8 2587 2589 O
childbearing 9 21 2590 2602 O
potential 22 31 2603 2612 O
must 32 36 2613 2617 O
agree 37 42 2618 2623 B-contraception_consent
to 43 45 2624 2626 I-contraception_consent
use 46 49 2627 2630 I-contraception_consent
adequate 50 58 2631 2639 I-contraception_consent
contraception 59 72 2640 2653 I-contraception_consent
( 73 74 2654 2655 O
hormonal 74 82 2655 2663 B-contraception_consent
or 83 85 2664 2666 O
barrier 86 93 2667 2674 B-contraception_consent
method 94 100 2675 2681 I-contraception_consent
of 101 103 2682 2684 I-contraception_consent
birth 104 109 2685 2690 I-contraception_consent
control 110 117 2691 2698 I-contraception_consent
) 117 118 2698 2699 O
prior 119 124 2700 2705 O
to 125 127 2706 2708 O
study 128 133 2709 2714 O
entry 134 139 2715 2720 O

a 0 1 2721 2722 O
screening 2 11 2723 2732 O
QTc 12 15 2733 2736 B-clinical_variable
> 16 17 2737 2738 O
= 17 18 2738 2739 O
450 19 22 2740 2743 B-lower_bound
msec 23 27 2744 2748 I-lower_bound
, 27 28 2748 2749 O
hypertriglyceridemia 29 49 2750 2770 B-chronic_disease
requiring 50 59 2771 2780 O
therapy 60 67 2781 2788 B-treatment

at 0 2 2789 2791 O
least 3 8 2792 2797 O
3 9 10 2798 2799 B-lower_bound
weeks 11 16 2800 2805 I-lower_bound
for 17 20 2806 2809 O
the 21 24 2810 2813 O
last 25 29 2814 2818 O
dose 30 34 2819 2823 O
of 35 37 2824 2826 O
biologic 38 46 2827 2835 B-treatment
therapy 47 54 2836 2843 I-treatment
( 55 56 2844 2845 O
eg 56 58 2845 2847 O
, 58 59 2847 2848 O
bevacizumab 60 71 2849 2860 B-treatment
) 71 72 2860 2861 O
or 73 75 2862 2864 O
cytotoxic 76 85 2865 2874 B-treatment
therapy 86 93 2875 2882 I-treatment
( 94 95 2883 2884 O
or 95 97 2884 2886 O
2 98 99 2887 2888 B-lower_bound
weeks 100 105 2889 2894 I-lower_bound
for 106 109 2895 2898 O
capecitabine 110 122 2899 2911 B-treatment
or 123 125 2912 2914 O
weekly 126 132 2915 2921 O
paclitaxel 133 143 2922 2932 B-treatment

left 0 4 2933 2937 B-clinical_variable
ventricular 5 16 2938 2949 I-clinical_variable
ejection 17 25 2950 2958 I-clinical_variable
fraction 26 34 2959 2967 I-clinical_variable
( 35 36 2968 2969 I-clinical_variable
LVEF 36 40 2969 2973 I-clinical_variable
) 40 41 2973 2974 I-clinical_variable
obtained 42 50 2975 2983 O
at 51 53 2984 2986 O
baseline 54 62 2987 2995 O
is 63 65 2996 2998 O
at 66 68 2999 3001 O
least 69 74 3002 3007 O
50 75 77 3008 3010 B-lower_bound
% 77 78 3010 3011 I-lower_bound
( 79 80 3012 3013 O
or 80 82 3013 3015 O
> 83 84 3016 3017 O
= 84 85 3017 3018 O
5 86 87 3019 3020 B-lower_bound
% 87 88 3020 3021 I-lower_bound
above 89 94 3022 3027 I-lower_bound
lower 95 100 3028 3033 I-lower_bound
institutional 101 114 3034 3047 I-lower_bound
limits 115 121 3048 3054 I-lower_bound
of 122 124 3055 3057 I-lower_bound
normal 125 131 3058 3064 I-lower_bound
whichever 132 141 3065 3074 O
is 142 144 3075 3077 O
higher 145 151 3078 3084 O
) 151 152 3084 3085 O

lobular 0 7 3086 3093 B-cancer
carcinoma 8 17 3094 3103 I-cancer
in 18 20 3104 3106 I-cancer
situ 21 25 3107 3111 I-cancer
, 25 26 3111 3112 O
contralateral 27 40 3113 3126 B-cancer
ductal 41 47 3127 3133 I-cancer
carcinoma 48 57 3134 3143 I-cancer
in 58 60 3144 3146 I-cancer
situ 61 65 3147 3151 I-cancer
, 65 66 3151 3152 O
or 67 69 3153 3155 O
contralateral 70 83 3156 3169 B-cancer
invasive 84 92 3170 3178 I-cancer
ductal 93 99 3179 3185 I-cancer
and/or 100 106 3186 3192 O
lobular 107 114 3193 3200 B-cancer
cancer 115 121 3201 3207 I-cancer
( 122 123 3208 3209 O
and 123 126 3209 3212 O
no 127 129 3213 3215 O
prior 130 135 3216 3221 B-treatment
adjuvant 136 144 3222 3230 I-treatment
chemotherapy 145 157 3231 3243 I-treatment
for 158 161 3244 3247 O
previous 162 170 3248 3256 O
breast 171 177 3257 3263 B-cancer
malignancy 178 188 3264 3274 I-cancer
) 188 189 3274 3275 O

osteoporosis 0 12 3276 3288 B-chronic_disease
, 12 13 3288 3289 O
prior 14 19 3290 3295 O
ductal 20 26 3296 3302 B-cancer
carcinoma 27 36 3303 3312 I-cancer
in 37 39 3313 3315 I-cancer
situ 40 44 3316 3320 I-cancer
[ 45 46 3321 3322 I-cancer
DCIS 46 50 3322 3326 I-cancer
] 50 51 3326 3327 I-cancer
) 51 52 3327 3328 O
, 52 53 3328 3329 O
or 54 56 3330 3332 O
who 57 60 3333 3336 O
receive 61 68 3337 3344 O
aromatase 69 78 3345 3354 B-treatment
inhibitors 79 89 3355 3365 I-treatment
for 90 93 3366 3369 O
prevention 94 104 3370 3380 O
or 105 107 3381 3383 O
treatment 108 117 3384 3393 B-treatment
of 118 120 3394 3396 O
breast 121 127 3397 3403 B-cancer
cancer 128 134 3404 3410 I-cancer
, 134 135 3410 3411 O
are 136 139 3412 3415 O
eligible 140 148 3416 3424 O

patients 0 8 3425 3433 O
treated 9 16 3434 3441 O
with 17 21 3442 3446 O
prior 22 27 3447 3452 B-treatment
anthracycline 28 41 3453 3466 I-treatment
therapy 42 49 3467 3474 I-treatment
as 50 52 3475 3477 O
neoadjuvant 53 64 3478 3489 B-treatment
, 64 65 3489 3490 O
adjuvant 66 74 3491 3499 O
, 74 75 3499 3500 O
or 76 78 3501 3503 O
metastatic 79 89 3504 3514 B-treatment
therapy 90 97 3515 3522 I-treatment

patients 0 8 3523 3531 O
who 9 12 3532 3535 O
are 13 16 3536 3539 O
hormone 17 24 3540 3547 B-cancer
- 24 25 3547 3548 I-cancer
receptor 25 33 3548 3556 I-cancer
positive 34 42 3557 3565 I-cancer
and 43 46 3566 3569 O
who 47 50 3570 3573 O
have 51 55 3574 3578 O
received 56 64 3579 3587 O
other 65 70 3588 3593 O
hormonal 71 79 3594 3602 O
agents 80 86 3603 3609 O
for 87 90 3610 3613 O
the 91 94 3614 3617 O
treatment 95 104 3618 3627 B-treatment
of 105 107 3628 3630 O
breast 108 114 3631 3637 B-cancer
cancer 115 121 3638 3644 I-cancer
( 122 123 3645 3646 O
e.g. 123 127 3646 3650 O
, 127 128 3650 3651 O
Fulvestrant 129 140 3652 3663 B-treatment
) 140 141 3663 3664 O
are 142 145 3665 3668 O
also 146 150 3669 3673 O
eligible 151 159 3674 3682 O

patients 0 8 3683 3691 O
who 9 12 3692 3695 O
have 13 17 3696 3700 O
had 18 21 3701 3704 O
a 22 23 3705 3706 O
prior 24 29 3707 3712 B-treatment
sentinel 30 38 3713 3721 I-treatment
lymph 39 44 3722 3727 I-treatment
node 45 49 3728 3732 I-treatment
biopsy 50 56 3733 3739 I-treatment
for 57 60 3740 3743 O
this 61 65 3744 3748 O
malignancy 66 76 3749 3759 B-cancer
are 77 80 3760 3763 O
eligible 81 89 3764 3772 O

patients 0 8 3773 3781 O
with 9 13 3782 3786 O
HER2 14 18 3787 3791 B-cancer
/ 18 19 3791 3792 I-cancer
neu 19 22 3792 3795 I-cancer
positive 23 31 3796 3804 I-cancer
breast 32 38 3805 3811 I-cancer
cancer 39 45 3812 3818 I-cancer
are 46 49 3819 3822 O
not 50 53 3823 3826 O
eligible 54 62 3827 3835 O

patients 0 8 3836 3844 O
with 9 13 3845 3849 O
estrogen 14 22 3850 3858 B-chronic_disease
receptor 23 31 3859 3867 I-chronic_disease
( 32 33 3868 3869 I-chronic_disease
ER)-positive 33 45 3869 3881 I-chronic_disease
disease 46 53 3882 3889 I-chronic_disease
are 54 57 3890 3893 O
required 58 66 3894 3902 O
to 67 69 3903 3905 O
have 70 74 3906 3910 O
relapse 75 82 3911 3918 O
or 83 85 3919 3921 O
progression 86 97 3922 3933 O
on 98 100 3934 3936 O
at 101 103 3937 3939 O
least 104 109 3940 3945 O
one 110 113 3946 3949 B-lower_bound
line 114 118 3950 3954 O
of 119 121 3955 3957 O
endocrine 122 131 3958 3967 B-treatment
therapy 132 139 3968 3975 I-treatment

prior 0 5 3976 3981 B-treatment
cumulative 6 16 3982 3992 I-treatment
doxorubicin 17 28 3993 4004 I-treatment
dose 29 33 4005 4009 B-clinical_variable
is 34 36 4010 4012 O
= 37 38 4013 4014 O
< 38 39 4014 4015 O
240 40 43 4016 4019 B-upper_bound
mg 44 46 4020 4022 I-upper_bound
/ 46 47 4022 4023 I-upper_bound
m^2 47 50 4023 4026 I-upper_bound
( 51 52 4027 4028 O
or 52 54 4028 4030 O
epirubicin 55 65 4031 4041 B-treatment
dose 66 70 4042 4046 O
is 71 73 4047 4049 O
= 74 75 4050 4051 O
< 75 76 4051 4052 O
400 77 80 4053 4056 B-upper_bound
mg 81 83 4057 4059 I-upper_bound
/ 83 84 4059 4060 I-upper_bound
m^2 84 87 4060 4063 I-upper_bound
) 87 88 4063 4064 O

should 0 6 4065 4071 O
a 7 8 4072 4073 O
woman 9 14 4074 4079 B-gender
become 15 21 4080 4086 B-pregnancy
pregnant 22 30 4087 4095 I-pregnancy

squamous 0 8 4096 4104 B-cancer
cell 9 13 4105 4109 I-cancer
carcinoma 14 23 4110 4119 I-cancer
of 24 26 4120 4122 O
the 27 30 4123 4126 O
skin 31 35 4127 4131 O
, 35 36 4131 4132 O
carcinoma 37 46 4133 4142 B-cancer
in 47 49 4143 4145 I-cancer
situ 50 54 4146 4150 I-cancer
of 55 57 4151 4153 O
the 58 61 4154 4157 O
cervix 62 68 4158 4164 O
( 69 70 4165 4166 O
for 70 73 4166 4169 O
phase 74 79 4170 4175 O
II 80 82 4176 4178 O
only 83 87 4179 4183 O
) 87 88 4183 4184 O

suspect 0 7 4185 4192 O
she 8 11 4193 4196 O
is 12 14 4197 4199 O
pregnant 15 23 4200 4208 B-pregnancy
while 24 29 4209 4214 O
participating 30 43 4215 4228 O
in 44 46 4229 4231 O
this 47 51 4232 4236 O
study 52 57 4237 4242 O

symptomatic 0 11 4243 4254 O
congestive 12 22 4255 4265 B-chronic_disease
heart 23 28 4266 4271 I-chronic_disease
failure 29 36 4272 4279 I-chronic_disease
, 36 37 4279 4280 O
unstable 38 46 4281 4289 O
angina 47 53 4290 4296 B-chronic_disease
pectoris 54 62 4297 4305 I-chronic_disease
, 62 63 4305 4306 O
cardiac 64 71 4307 4314 B-chronic_disease
arrhythmia 72 82 4315 4325 I-chronic_disease
, 82 83 4325 4326 O
or 84 86 4327 4329 O
psychiatric 87 98 4330 4341 B-chronic_disease
illness 99 106 4342 4349 I-chronic_disease
/ 106 107 4349 4350 O
social 107 113 4350 4356 O
situations 114 124 4357 4367 O
that 125 129 4368 4372 O
would 130 135 4373 4378 O
limit 136 141 4379 4384 O
compliance 142 152 4385 4395 O
with 153 157 4396 4400 O
study 158 163 4401 4406 O
requirements 164 176 4407 4419 O

tamoxifen 0 9 4420 4429 B-treatment
therapy 10 17 4430 4437 I-treatment
or 18 20 4438 4440 O
other 21 26 4441 4446 O
hormonal 27 35 4447 4455 O
agents 36 42 4456 4462 O
should 43 49 4463 4469 O
be 50 52 4470 4472 O
discontinued 53 65 4473 4485 O
at 66 68 4486 4488 O
least 69 74 4489 4494 O
1 75 76 4495 4496 B-lower_bound
week 77 81 4497 4501 I-lower_bound
before 82 88 4502 4508 O
the 89 92 4509 4512 O
patient 93 100 4513 4520 O
is 101 103 4521 4523 O
enrolled 104 112 4524 4532 O
on 113 115 4533 4535 O
this 116 120 4536 4540 O
study 121 126 4541 4546 O

the 0 3 4547 4550 O
tumor 4 9 4551 4556 B-cancer
must 10 14 4557 4561 O
be 15 17 4562 4564 O
human 18 23 4565 4570 O
epidermal 24 33 4571 4580 O
growth 34 40 4581 4587 O
factor 41 47 4588 4594 O
receptor 48 56 4595 4603 O
2 57 58 4604 4605 O
( 59 60 4606 4607 O
Her2)/neu 60 69 4607 4616 O
negative 70 78 4617 4625 O
( 79 80 4626 4627 O
by 80 82 4627 4629 O
DAKO 83 87 4630 4634 B-treatment
HercepTest 88 98 4635 4645 I-treatment
, 98 99 4645 4646 O
fluorescence 100 112 4647 4659 B-treatment
based 113 118 4660 4665 I-treatment
in 119 121 4666 4668 I-treatment
situ 122 126 4669 4673 I-treatment
hybridization 127 140 4674 4687 I-treatment
[ 141 142 4688 4689 I-treatment
FISH 142 146 4689 4693 I-treatment
] 146 147 4693 4694 I-treatment
, 147 148 4694 4695 O
or 149 151 4696 4698 O
other 152 157 4699 4704 O
approved 158 166 4705 4713 O
assay 167 172 4714 4719 O
) 172 173 4719 4720 O

there 0 5 4721 4726 O
should 6 12 4727 4733 O
be 13 15 4734 4736 O
a 16 17 4737 4738 O
least 18 23 4739 4744 O
a 24 25 4745 4746 O
1 26 27 4747 4748 B-lower_bound
- 27 28 4748 4749 I-lower_bound
week 28 32 4749 4753 I-lower_bound
interval 33 41 4754 4762 O
between 42 49 4763 4770 O
last 50 54 4771 4775 O
dose 55 59 4776 4780 O
of 60 62 4781 4783 O
endocrine 63 72 4784 4793 B-treatment
therapy 73 80 4794 4801 I-treatment
and 81 84 4802 4805 O
protocol 85 93 4806 4814 B-treatment
therapy 94 101 4815 4822 I-treatment

up 0 2 4823 4825 O
to 3 5 4826 4828 O
30 6 8 4829 4831 B-upper_bound
days 9 13 4832 4836 I-upper_bound
prior 14 19 4837 4842 I-upper_bound
to 20 22 4843 4845 O
beginning 23 32 4846 4855 O
protocol 33 41 4856 4864 O
therapy 42 49 4865 4872 B-treatment

